Altering S1P levels in serum or in specific tissues appears as a novel therapeutic strategy to modulate cellular functions under certain pathophysiological conditions, i.e., we could recently show that stimulating osteoblast activity via inhibition of S1P degradation by targeting the S1P lyase is a new concept to treat osteoporosis [40]. The gene discussed is MBTPS1; the disease is osteoporosis.